Ignite Creation Date:
2025-12-24 @ 5:36 PM
Ignite Modification Date:
2026-06-01 @ 1:49 AM
Study NCT ID:
NCT04780568
Status:
RECRUITING
Last Update Posted:
2025-12-09
First Post:
2021-02-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Sponsor:
Ohio State University Comprehensive Cancer Center
Organization: